Notably, high KPNB1 expression (P = 2.1 × 10−2 and 1.0 × 10−14) or low SMARCC2 levels (P = 2.4 × 10−2 and 6.9 × 10−11) were linked to poor outcome of NB patients in public datasets (TARGET and GSE62564, Figure 3A,B). This evidence concerns the gene KPNB1 and neuroblastoma.